Glp-1 Receptor Agonists For Eating Disorders

Overview of Glp-1 Receptor Agonists For Eating Disorders

Glucagon-like peptide-1 ( GLP-1 ) agonists are types of medications originally approved by the FDA to treat Type 2 diabetes and were later approved by the FDA for chronic weight management (i.e., Mounjaro, Ozempic, Saxenda, Victoza, Wegovy, Zepbound etc.). Common types of GLP-1's include semaglutide, liraglutide and tirzepatide. Lower doses of the drugs are used to treat Type 2 diabetes while ...

Such details provide a deeper understanding and appreciation for Glp-1 Receptor Agonists For Eating Disorders.

Agonist use in patients with eating disorders should be approached cautiously. A recent systematic review and meta-analysis (Eat Weight Disord. 2025; 30:10) explored the potential of glucagon-like peptide-1 ( GLP-1 ) receptor agonists in treating eating disorders , particularly binge eating disorder (BED). GLP-1 is a natural gut hormone released after eating . It is an anorexigenic hormone ...

This particular example perfectly highlights why Glp-1 Receptor Agonists For Eating Disorders is so captivating.

Purpose Glucagon-like peptide-1 ( GLP-1 ) receptor agonists have shown potential in managing eating disorders (EDs). Recent studies highlight their effects on pathophysiological pathways, indicating their therapeutic promise, particularly for binge eating disorder (BED). This systematic review evaluates the therapeutic effects of GLP-1 agonists on BED, focusing on weight management and eating ...